Less frequent dosing could provide Eli Lilly’s Ebglyss room to rival Sanofi and Regeneron’s blockbuster Dupixent.
The separation of Ebglyss from Dupixent and Adbry/Adtralza will depend on real-world clinical benefits, patient experience ...
AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...
The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to ...
Ebglyss' approval highlights the opportunity that exists in the AD space, and may have potential advantages in efficacy and ...
Of the interviewed providers, 53.4% had experience with food allergy clinical trials, and 85% offered oral immunotherapy to ...
The US Food and Drug Administration has approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic ...
The label expansion provides a new option for the hundreds of thousands of Americans with inadequately controlled COPD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback